What are the treatment options for ADHD when Focalin (dexmethylphenidate) and Adderall (mixed amphetamine salts) are unavailable?

Alternative ADHD Treatment Options When Focalin and Adderall Are Unavailable

First-Line Alternative: Methylphenidate Formulations

Methylphenidate remains the strongest evidence-based alternative to Adderall and Focalin, with 70-80% response rates and the most robust clinical trial data among all ADHD medications. 1

Immediate-Release Methylphenidate

• Start at 5 mg twice daily (morning and midday), titrate by 5-10 mg weekly up to maximum 60 mg/day in divided doses 1
• Provides 3-4 hours of symptom control per dose 1
• Requires multiple daily doses but allows flexible timing adjustments 1

Extended-Release Methylphenidate (Concerta)

• Strongly preferred over immediate-release due to once-daily dosing, better adherence, more consistent symptom control, and lower diversion potential 1, 2
• Start at 18 mg once daily in the morning, increase by 18 mg weekly based on response 2
• Maximum dose 54-72 mg daily 2
• OROS delivery system provides 12 hours of coverage with ascending plasma levels 1
• Tamper-resistant formulation reduces abuse risk, particularly important for adolescents 1, 2

Key Advantage

• Approximately 40% of patients respond to both methylphenidate and amphetamines, while 40% respond to only one class—if Adderall failed, methylphenidate may still work 2

---

Second-Line Alternative: Lisdexamfetamine (Vyvanse)

Lisdexamfetamine is a prodrug amphetamine formulation with once-daily dosing and reduced abuse potential compared to immediate-release amphetamines. 1

• Start at 20-30 mg once daily in the morning, titrate by 10-20 mg weekly 1, 3
• Maximum dose 70 mg daily 1
• Provides 11-13 hours of symptom coverage 4
• Prodrug design requires enzymatic activation, lowering abuse potential 1, 4
• 70-80% response rate when properly titrated 1

---

Non-Stimulant Options (When Stimulants Are Contraindicated or Failed)

Atomoxetine (First-Line Non-Stimulant)

Atomoxetine is the only FDA-approved non-stimulant for adult ADHD and should be the primary non-stimulant choice. 1, 5

• Target dose 60-100 mg daily (maximum 1.4 mg/kg/day or 100 mg/day, whichever is lower) 1
• Start at 40 mg daily, titrate every 7-14 days to 60 mg, then 80 mg 1
• Requires 6-12 weeks to achieve full therapeutic effect—significantly longer than stimulants which work within days 1
• Medium-range effect size of 0.7 compared to stimulants (1.0) 1, 2
• No abuse potential—uncontrolled substance 1
• Provides 24-hour symptom coverage 1
• FDA black box warning for increased suicidal ideation risk—monitor closely, especially in first few months 1

Best for: Patients with substance abuse history, comorbid anxiety, or when stimulants are contraindicated 1, 5

Extended-Release Guanfacine (Alpha-2 Agonist)

• Start at 1 mg once daily in evening, titrate by 1 mg weekly 1, 3
• Target dose 0.05-0.12 mg/kg/day, maximum 7 mg/day 1, 3
• Effect size approximately 0.7 1, 2
• Requires 2-4 weeks for full effect 1
• FDA-approved as monotherapy or adjunctive therapy to stimulants 1
• Never abruptly discontinue—taper by 1 mg every 3-7 days to avoid rebound hypertension 1

Best for: Comorbid tics, Tourette's, sleep disturbances, oppositional symptoms, or as adjunctive therapy when stimulants alone are insufficient 1, 3, 4

Extended-Release Clonidine (Alpha-2 Agonist)

• Similar efficacy and effect size to guanfacine (approximately 0.7) 1, 2
• Requires 2-4 weeks for full effect 1
• More sedating than guanfacine—dose in evening 1
• FDA-approved as monotherapy or adjunctive therapy 1

Best for: Similar indications to guanfacine, particularly when sedation is desired for sleep disturbances 1

Bupropion (Second-Line Non-Stimulant)

Bupropion is explicitly positioned as a second-line agent for ADHD—consider only when two or more stimulants have failed or when active substance abuse disorder is present. 1

• Start at 100-150 mg SR daily or 150 mg XL daily 1
• Titrate to 100-150 mg twice daily (SR) or 150-300 mg daily (XL) 1
• Maximum 450 mg/day 1
• More rapid onset than atomoxetine but slower than stimulants 1
• No single antidepressant is proven to effectively treat both ADHD and depression—bupropion is not a substitute for stimulants 1
• Common side effects: headache, insomnia, anxiety 1
• Seizure risk increases at higher doses, especially when combined with stimulants 1

Best for: Comorbid depression, smoking cessation needs, or when atomoxetine/alpha-2 agonists have failed 1, 5

Viloxazine Extended-Release (Emerging Non-Stimulant)

• Repurposed antidepressant classified as serotonin-norepinephrine modulating agent 1
• FDA-approved for children and adults with ADHD 1
• Favorable efficacy and tolerability in pivotal trials 1
• Limited long-term data compared to other options 2

---

Treatment Algorithm by Clinical Scenario

For School-Age Children and Adolescents (6-18 years)

1. First-line: Extended-release methylphenidate (Concerta) 18 mg daily, titrate weekly 6, 1, 2
2. If inadequate response: Switch to lisdexamfetamine 20-30 mg daily 1
3. If stimulants fail/contraindicated: Atomoxetine 40-100 mg daily 6, 1
4. For comorbid aggression/tics: Add guanfacine ER 1-4 mg nightly as adjunctive therapy 6, 1, 3
5. Always combine with behavioral interventions: Parent training and classroom management 6, 3

For Adults

1. First-line: Methylphenidate 5-20 mg three times daily OR extended-release formulation 1, 2
2. Alternative first-line: Lisdexamfetamine 30-70 mg daily 1
3. If stimulants fail/contraindicated: Atomoxetine 60-100 mg daily 1, 2
4. For substance abuse history: Atomoxetine or long-acting methylphenidate formulations 1, 5
5. Consider CBT: Most effective psychotherapy for adult ADHD, especially when combined with medication 1

For Preschool-Age Children (4-5 years)

1. First-line: Evidence-based behavioral interventions (parent training) 6
2. If behavioral interventions fail AND moderate-to-severe dysfunction: Methylphenidate may be considered 6
3. Other stimulants/non-stimulants: Not adequately studied in this age group 6

---

Critical Monitoring Parameters (All Medications)

• Baseline: Blood pressure, pulse, height, weight, cardiac history screening 1, 2
• During titration: Weekly symptom ratings, blood pressure/pulse at each dose adjustment 1
• Maintenance: Quarterly vital signs (adults), annual assessment with height/weight at every visit (children) 1
• Atomoxetine-specific: Suicidality screening at every visit, especially first few months 1
• Alpha-2 agonists: Never abruptly discontinue—taper to avoid rebound hypertension 1

---

Common Pitfalls to Avoid

• Do not underdose stimulants—70-80% response rates require proper titration to maximum therapeutic doses 1, 3
• Do not assume methylphenidate and amphetamines are interchangeable—40% of patients respond to only one class 2
• Do not expect rapid results from atomoxetine—requires 6-12 weeks for full effect, unlike stimulants (days) 1
• Do not use bupropion as first-line—it is explicitly second-line after stimulant failure 1
• Do not prescribe benzodiazepines for comorbid anxiety—they may reduce self-control and have disinhibiting effects 1, 3
• Do not stop guanfacine/clonidine abruptly—taper to prevent rebound hypertension 1